Panic disorder: Neurobiology and mechanisms of cardiac risks [ 2003 - 2005 ]

Research Grant

Researchers: Prof Murray Esler (Principal investigator) ,  A/Pr Elisabeth Lambert ,  Prof Jeffrey Richards

Brief description Some people are subject to episodes of recurring, often inexplicable anxiety which are very unpleasant and accompanied by physical symptoms such as sweating, palpitations, tremor and a sensation of suffocation. Recurring attacks over a period of months, or years, forms the basis for the diagnosis of panic disorder. It has until recently been felt that although panic disorder was distressing and disabling, it did not constitute a risk to life. Sufferers often fear that they have heart disease, because of the nature of their symptoms, but have been reassured that this is not the case. Recent epidemiological studies, however, indicate that there is an increased risk of heart risk in patients with panic disorder. Our hypotheses in this research are as follows: That panic disorder is characterised by increased release of the brain chemical messenger, serotonin, which is reversed by drug treatment with the most widely used class of drugs for this disorder, selective serotonin reuptake blockers That changes in an automatic stimulatory part of the nervous system, has primary importance in the disorder, in both genetically predisposing to panic disorder, and in mediating heart risk. That weight gain during therapy, a very common problem, is due to inhibition of brain serotonin release. We will test all these propositions using state of the art clinical scientific methods. Panic disorder has an important cardiological dimension which needs to be better understood for cardiac protection to be achieved in panic disorder patients. Our study of the mechanisms of cardiac risk should provide this. We will also provide very direct, valid measurements of chemical messenger release in the brain of panic disorder sufferers, using our unique methods. These should give a new understanding of the brain chemistry abnormalities of panic disorder, and the mechanism of action of the selective serotonin reuptake inhibitors.

Funding Amount $AUD 414,375.00

Funding Scheme NHMRC Project Grants

Notes Standard Project Grant